DENTSPLY SIRONA Inc.
DENTSPLY SIRONA Inc. (XRAY) Stock Competitors & Peer Comparison
See (XRAY) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| XRAY | $16.03 | -2.61% | 3.2B | -3.59 | -$4.47 | +3.97% |
| ISRG | $495.86 | +1.48% | 177.7B | 69.06 | $7.18 | N/A |
| BDX | $185.32 | +0.92% | 53.1B | 35.93 | $5.16 | +2.19% |
| BDXA | $59.24 | -2.24% | 48.7B | 21.44 | $2.76 | +2.19% |
| ALC | $91.86 | -0.04% | 45.4B | 40.83 | $2.25 | +0.36% |
| RMD | $275.16 | +0.61% | 40.4B | 30.86 | $8.92 | +0.77% |
| WST | $263.51 | -5.59% | 18.9B | 39.48 | $6.67 | +0.31% |
| BAX | $29.22 | +1.56% | 15B | -56.19 | -$0.52 | +2.73% |
| COO | $74.59 | +1.07% | 14.9B | 36.03 | $2.07 | N/A |
| HOLX | $66.50 | +0.61% | 14.8B | 27.94 | $2.38 | N/A |
Stock Comparison
XRAY vs ISRG Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, ISRG has a market cap of 177.7B. Regarding current trading prices, XRAY is priced at $16.03, while ISRG trades at $495.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas ISRG's P/E ratio is 69.06. In terms of profitability, XRAY's ROE is -0.38%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, XRAY is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check ISRG's competition here
XRAY vs BDX Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, BDX has a market cap of 53.1B. Regarding current trading prices, XRAY is priced at $16.03, while BDX trades at $185.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas BDX's P/E ratio is 35.93. In terms of profitability, XRAY's ROE is -0.38%, compared to BDX's ROE of +0.06%. Regarding short-term risk, XRAY is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check BDX's competition here
XRAY vs BDXA Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, BDXA has a market cap of 48.7B. Regarding current trading prices, XRAY is priced at $16.03, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas BDXA's P/E ratio is 21.44. In terms of profitability, XRAY's ROE is -0.38%, compared to BDXA's ROE of +0.06%. Regarding short-term risk, XRAY is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check BDXA's competition here
XRAY vs ALC Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, ALC has a market cap of 45.4B. Regarding current trading prices, XRAY is priced at $16.03, while ALC trades at $91.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas ALC's P/E ratio is 40.83. In terms of profitability, XRAY's ROE is -0.38%, compared to ALC's ROE of +0.07%. Regarding short-term risk, XRAY is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check ALC's competition here
XRAY vs RMD Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, RMD has a market cap of 40.4B. Regarding current trading prices, XRAY is priced at $16.03, while RMD trades at $275.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas RMD's P/E ratio is 30.86. In terms of profitability, XRAY's ROE is -0.38%, compared to RMD's ROE of +0.25%. Regarding short-term risk, XRAY is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check RMD's competition here
XRAY vs WST Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, WST has a market cap of 18.9B. Regarding current trading prices, XRAY is priced at $16.03, while WST trades at $263.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas WST's P/E ratio is 39.48. In terms of profitability, XRAY's ROE is -0.38%, compared to WST's ROE of +0.24%. Regarding short-term risk, XRAY is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check WST's competition here
XRAY vs BAX Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, BAX has a market cap of 15B. Regarding current trading prices, XRAY is priced at $16.03, while BAX trades at $29.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas BAX's P/E ratio is -56.19. In terms of profitability, XRAY's ROE is -0.38%, compared to BAX's ROE of -0.08%. Regarding short-term risk, XRAY is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check BAX's competition here
XRAY vs COO Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, COO has a market cap of 14.9B. Regarding current trading prices, XRAY is priced at $16.03, while COO trades at $74.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas COO's P/E ratio is 36.03. In terms of profitability, XRAY's ROE is -0.38%, compared to COO's ROE of +0.05%. Regarding short-term risk, XRAY is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check COO's competition here
XRAY vs HOLX Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, HOLX has a market cap of 14.8B. Regarding current trading prices, XRAY is priced at $16.03, while HOLX trades at $66.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas HOLX's P/E ratio is 27.94. In terms of profitability, XRAY's ROE is -0.38%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, XRAY is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check HOLX's competition here
XRAY vs BDXB Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, XRAY is priced at $16.03, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas BDXB's P/E ratio is 7.60. In terms of profitability, XRAY's ROE is -0.38%, compared to BDXB's ROE of +0.06%. Regarding short-term risk, XRAY is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check BDXB's competition here
XRAY vs ATR Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, ATR has a market cap of 10.6B. Regarding current trading prices, XRAY is priced at $16.03, while ATR trades at $160.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas ATR's P/E ratio is 29.42. In terms of profitability, XRAY's ROE is -0.38%, compared to ATR's ROE of +0.15%. Regarding short-term risk, XRAY is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check ATR's competition here
XRAY vs MASI Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, MASI has a market cap of 8.9B. Regarding current trading prices, XRAY is priced at $16.03, while MASI trades at $164.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas MASI's P/E ratio is -30.15. In terms of profitability, XRAY's ROE is -0.38%, compared to MASI's ROE of -0.41%. Regarding short-term risk, XRAY is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check MASI's competition here
XRAY vs STVN Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, STVN has a market cap of 7.2B. Regarding current trading prices, XRAY is priced at $16.03, while STVN trades at $26.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas STVN's P/E ratio is 49.07. In terms of profitability, XRAY's ROE is -0.38%, compared to STVN's ROE of +0.09%. Regarding short-term risk, XRAY is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check STVN's competition here
XRAY vs RGEN Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, RGEN has a market cap of 6.8B. Regarding current trading prices, XRAY is priced at $16.03, while RGEN trades at $121.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas RGEN's P/E ratio is -289.85. In terms of profitability, XRAY's ROE is -0.38%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, XRAY is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check RGEN's competition here
XRAY vs TFX Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, TFX has a market cap of 5.2B. Regarding current trading prices, XRAY is priced at $16.03, while TFX trades at $117.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas TFX's P/E ratio is 36.29. In terms of profitability, XRAY's ROE is -0.38%, compared to TFX's ROE of +0.03%. Regarding short-term risk, XRAY is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check TFX's competition here
XRAY vs BLCO Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, BLCO has a market cap of 5.1B. Regarding current trading prices, XRAY is priced at $16.03, while BLCO trades at $14.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas BLCO's P/E ratio is -14.03. In terms of profitability, XRAY's ROE is -0.38%, compared to BLCO's ROE of -0.08%. Regarding short-term risk, XRAY is less volatile compared to BLCO. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check BLCO's competition here
XRAY vs MMSI Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, MMSI has a market cap of 5B. Regarding current trading prices, XRAY is priced at $16.03, while MMSI trades at $84.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas MMSI's P/E ratio is 41.51. In terms of profitability, XRAY's ROE is -0.38%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, XRAY is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check MMSI's competition here
XRAY vs HAE Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, XRAY is priced at $16.03, while HAE trades at $75.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas HAE's P/E ratio is 22.72. In terms of profitability, XRAY's ROE is -0.38%, compared to HAE's ROE of +0.18%. Regarding short-term risk, XRAY is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check HAE's competition here
XRAY vs ICUI Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, ICUI has a market cap of 3.2B. Regarding current trading prices, XRAY is priced at $16.03, while ICUI trades at $129.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas ICUI's P/E ratio is -34.01. In terms of profitability, XRAY's ROE is -0.38%, compared to ICUI's ROE of -0.05%. Regarding short-term risk, XRAY is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check ICUI's competition here
XRAY vs WRBY Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, WRBY has a market cap of 3B. Regarding current trading prices, XRAY is priced at $16.03, while WRBY trades at $24.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas WRBY's P/E ratio is -203.21. In terms of profitability, XRAY's ROE is -0.38%, compared to WRBY's ROE of -0.04%. Regarding short-term risk, XRAY is more volatile compared to WRBY. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check WRBY's competition here
XRAY vs NNNN Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, NNNN has a market cap of 2.2B. Regarding current trading prices, XRAY is priced at $16.03, while NNNN trades at $50.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas NNNN's P/E ratio is 1019.30. In terms of profitability, XRAY's ROE is -0.38%, compared to NNNN's ROE of +0.14%. Regarding short-term risk, XRAY is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check NNNN's competition here
XRAY vs LMAT Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, XRAY is priced at $16.03, while LMAT trades at $82.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas LMAT's P/E ratio is 41.92. In terms of profitability, XRAY's ROE is -0.38%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, XRAY is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check LMAT's competition here
XRAY vs QDEL Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, QDEL has a market cap of 1.9B. Regarding current trading prices, XRAY is priced at $16.03, while QDEL trades at $27.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas QDEL's P/E ratio is -5.24. In terms of profitability, XRAY's ROE is -0.38%, compared to QDEL's ROE of -0.11%. Regarding short-term risk, XRAY is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check QDEL's competition here
XRAY vs AZTA Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, AZTA has a market cap of 1.6B. Regarding current trading prices, XRAY is priced at $16.03, while AZTA trades at $34.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas AZTA's P/E ratio is -10.53. In terms of profitability, XRAY's ROE is -0.38%, compared to AZTA's ROE of -0.04%. Regarding short-term risk, XRAY is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check AZTA's competition here
XRAY vs ATRC Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, ATRC has a market cap of 1.6B. Regarding current trading prices, XRAY is priced at $16.03, while ATRC trades at $31.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas ATRC's P/E ratio is -38.89. In terms of profitability, XRAY's ROE is -0.38%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, XRAY is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check ATRC's competition here
XRAY vs NVCR Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, NVCR has a market cap of 1.3B. Regarding current trading prices, XRAY is priced at $16.03, while NVCR trades at $12.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas NVCR's P/E ratio is -7.72. In terms of profitability, XRAY's ROE is -0.38%, compared to NVCR's ROE of -0.45%. Regarding short-term risk, XRAY is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check NVCR's competition here
XRAY vs BLFS Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, BLFS has a market cap of 1.1B. Regarding current trading prices, XRAY is priced at $16.03, while BLFS trades at $22.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas BLFS's P/E ratio is -118.84. In terms of profitability, XRAY's ROE is -0.38%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, XRAY is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check BLFS's competition here
XRAY vs PLSE Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, PLSE has a market cap of 1B. Regarding current trading prices, XRAY is priced at $16.03, while PLSE trades at $14.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas PLSE's P/E ratio is -15.08. In terms of profitability, XRAY's ROE is -0.38%, compared to PLSE's ROE of -0.71%. Regarding short-term risk, XRAY is more volatile compared to PLSE. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check PLSE's competition here
XRAY vs STAA Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, STAA has a market cap of 950.9M. Regarding current trading prices, XRAY is priced at $16.03, while STAA trades at $19.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas STAA's P/E ratio is -13.33. In terms of profitability, XRAY's ROE is -0.38%, compared to STAA's ROE of -0.18%. Regarding short-term risk, XRAY is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check STAA's competition here
XRAY vs KMTS Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, KMTS has a market cap of 849.8M. Regarding current trading prices, XRAY is priced at $16.03, while KMTS trades at $16.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas KMTS's P/E ratio is -3.23. In terms of profitability, XRAY's ROE is -0.38%, compared to KMTS's ROE of +0.27%. Regarding short-term risk, XRAY is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check KMTS's competition here
XRAY vs ATRI Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, XRAY is priced at $16.03, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas ATRI's P/E ratio is 64.50. In terms of profitability, XRAY's ROE is -0.38%, compared to ATRI's ROE of +0.04%. Regarding short-term risk, XRAY is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check ATRI's competition here
XRAY vs ANGO Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, ANGO has a market cap of 374.6M. Regarding current trading prices, XRAY is priced at $16.03, while ANGO trades at $9.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas ANGO's P/E ratio is -11.11. In terms of profitability, XRAY's ROE is -0.38%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, XRAY is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check ANGO's competition here
XRAY vs NYXH Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, NYXH has a market cap of 283.7M. Regarding current trading prices, XRAY is priced at $16.03, while NYXH trades at $7.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas NYXH's P/E ratio is -3.25. In terms of profitability, XRAY's ROE is -0.38%, compared to NYXH's ROE of -0.65%. Regarding short-term risk, XRAY is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check NYXH's competition here
XRAY vs OSUR Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, OSUR has a market cap of 251.3M. Regarding current trading prices, XRAY is priced at $16.03, while OSUR trades at $3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas OSUR's P/E ratio is -8.00. In terms of profitability, XRAY's ROE is -0.38%, compared to OSUR's ROE of -0.08%. Regarding short-term risk, XRAY is more volatile compared to OSUR. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check OSUR's competition here
XRAY vs SMTI Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, SMTI has a market cap of 226.9M. Regarding current trading prices, XRAY is priced at $16.03, while SMTI trades at $25.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas SMTI's P/E ratio is -19.05. In terms of profitability, XRAY's ROE is -0.38%, compared to SMTI's ROE of -0.29%. Regarding short-term risk, XRAY is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check SMTI's competition here
XRAY vs STXS Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, STXS has a market cap of 202.6M. Regarding current trading prices, XRAY is priced at $16.03, while STXS trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas STXS's P/E ratio is -7.24. In terms of profitability, XRAY's ROE is -0.38%, compared to STXS's ROE of -2.17%. Regarding short-term risk, XRAY is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check STXS's competition here
XRAY vs UTMD Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, UTMD has a market cap of 188.7M. Regarding current trading prices, XRAY is priced at $16.03, while UTMD trades at $58.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas UTMD's P/E ratio is 15.53. In terms of profitability, XRAY's ROE is -0.38%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, XRAY is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check UTMD's competition here
XRAY vs PDEX Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, PDEX has a market cap of 160.1M. Regarding current trading prices, XRAY is priced at $16.03, while PDEX trades at $49.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas PDEX's P/E ratio is 17.79. In terms of profitability, XRAY's ROE is -0.38%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, XRAY is more volatile compared to PDEX. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check PDEX's competition here
XRAY vs KRMD Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, KRMD has a market cap of 159.6M. Regarding current trading prices, XRAY is priced at $16.03, while KRMD trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas KRMD's P/E ratio is -28.83. In terms of profitability, XRAY's ROE is -0.38%, compared to KRMD's ROE of -0.30%. Regarding short-term risk, XRAY is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check KRMD's competition here
XRAY vs INFU Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, INFU has a market cap of 126.1M. Regarding current trading prices, XRAY is priced at $16.03, while INFU trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas INFU's P/E ratio is 40.07. In terms of profitability, XRAY's ROE is -0.38%, compared to INFU's ROE of +0.08%. Regarding short-term risk, XRAY is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check INFU's competition here
XRAY vs MBOT Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, MBOT has a market cap of 108M. Regarding current trading prices, XRAY is priced at $16.03, while MBOT trades at $2.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas MBOT's P/E ratio is -4.64. In terms of profitability, XRAY's ROE is -0.38%, compared to MBOT's ROE of -0.85%. Regarding short-term risk, XRAY is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check MBOT's competition here
XRAY vs ZJYL Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, ZJYL has a market cap of 101.5M. Regarding current trading prices, XRAY is priced at $16.03, while ZJYL trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas ZJYL's P/E ratio is 32.43. In terms of profitability, XRAY's ROE is -0.38%, compared to ZJYL's ROE of +0.13%. Regarding short-term risk, XRAY is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check ZJYL's competition here
XRAY vs ZTEK Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, ZTEK has a market cap of 92.1M. Regarding current trading prices, XRAY is priced at $16.03, while ZTEK trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas ZTEK's P/E ratio is -12.57. In terms of profitability, XRAY's ROE is -0.38%, compared to ZTEK's ROE of -0.59%. Regarding short-term risk, XRAY is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check ZTEK's competition here
XRAY vs AKYA Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, XRAY is priced at $16.03, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas AKYA's P/E ratio is -1.34. In terms of profitability, XRAY's ROE is -0.38%, compared to AKYA's ROE of -5.06%. Regarding short-term risk, XRAY is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check AKYA's competition here
XRAY vs DXR Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, DXR has a market cap of 50.8M. Regarding current trading prices, XRAY is priced at $16.03, while DXR trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas DXR's P/E ratio is -113.78. In terms of profitability, XRAY's ROE is -0.38%, compared to DXR's ROE of +0.02%. Regarding short-term risk, XRAY is more volatile compared to DXR. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check DXR's competition here
XRAY vs OMIC Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, XRAY is priced at $16.03, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas OMIC's P/E ratio is -0.58. In terms of profitability, XRAY's ROE is -0.38%, compared to OMIC's ROE of -0.58%. Regarding short-term risk, XRAY is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check OMIC's competition here
XRAY vs IGAP Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, XRAY is priced at $16.03, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas IGAP's P/E ratio is -10.52. In terms of profitability, XRAY's ROE is -0.38%, compared to IGAP's ROE of +3.93%. Regarding short-term risk, XRAY is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check IGAP's competition here
XRAY vs WOK Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, WOK has a market cap of 46.8M. Regarding current trading prices, XRAY is priced at $16.03, while WOK trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas WOK's P/E ratio is -3.07. In terms of profitability, XRAY's ROE is -0.38%, compared to WOK's ROE of -0.30%. Regarding short-term risk, XRAY is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check WOK's competition here
XRAY vs MLSS Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, MLSS has a market cap of 46.3M. Regarding current trading prices, XRAY is priced at $16.03, while MLSS trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas MLSS's P/E ratio is -9.83. In terms of profitability, XRAY's ROE is -0.38%, compared to MLSS's ROE of -0.83%. Regarding short-term risk, XRAY is more volatile compared to MLSS. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check MLSS's competition here
XRAY vs NEPH Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, NEPH has a market cap of 37.8M. Regarding current trading prices, XRAY is priced at $16.03, while NEPH trades at $3.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas NEPH's P/E ratio is 44.63. In terms of profitability, XRAY's ROE is -0.38%, compared to NEPH's ROE of +0.09%. Regarding short-term risk, XRAY is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check NEPH's competition here
XRAY vs POCI Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, POCI has a market cap of 36.6M. Regarding current trading prices, XRAY is priced at $16.03, while POCI trades at $4.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas POCI's P/E ratio is -5.25. In terms of profitability, XRAY's ROE is -0.38%, compared to POCI's ROE of -0.54%. Regarding short-term risk, XRAY is more volatile compared to POCI. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check POCI's competition here
XRAY vs FEMY Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, FEMY has a market cap of 29.1M. Regarding current trading prices, XRAY is priced at $16.03, while FEMY trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas FEMY's P/E ratio is -0.98. In terms of profitability, XRAY's ROE is -0.38%, compared to FEMY's ROE of -3.92%. Regarding short-term risk, XRAY is more volatile compared to FEMY. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check FEMY's competition here
XRAY vs SDC Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, XRAY is priced at $16.03, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas SDC's P/E ratio is -0.03. In terms of profitability, XRAY's ROE is -0.38%, compared to SDC's ROE of -1.96%. Regarding short-term risk, XRAY is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check SDC's competition here
XRAY vs NXGLW Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, NXGLW has a market cap of 25.8M. Regarding current trading prices, XRAY is priced at $16.03, while NXGLW trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas NXGLW's P/E ratio is -0.24. In terms of profitability, XRAY's ROE is -0.38%, compared to NXGLW's ROE of -0.63%. Regarding short-term risk, XRAY is more volatile compared to NXGLW. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check NXGLW's competition here
XRAY vs HBIO Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, HBIO has a market cap of 25M. Regarding current trading prices, XRAY is priced at $16.03, while HBIO trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas HBIO's P/E ratio is -0.43. In terms of profitability, XRAY's ROE is -0.38%, compared to HBIO's ROE of -1.10%. Regarding short-term risk, XRAY is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check HBIO's competition here
XRAY vs IVC Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, XRAY is priced at $16.03, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas IVC's P/E ratio is -0.79. In terms of profitability, XRAY's ROE is -0.38%, compared to IVC's ROE of -0.46%. Regarding short-term risk, XRAY is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check IVC's competition here
XRAY vs RVP Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, RVP has a market cap of 21.3M. Regarding current trading prices, XRAY is priced at $16.03, while RVP trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas RVP's P/E ratio is -0.93. In terms of profitability, XRAY's ROE is -0.38%, compared to RVP's ROE of -0.27%. Regarding short-term risk, XRAY is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check RVP's competition here
XRAY vs NXGL Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, NXGL has a market cap of 18.1M. Regarding current trading prices, XRAY is priced at $16.03, while NXGL trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas NXGL's P/E ratio is -5.24. In terms of profitability, XRAY's ROE is -0.38%, compared to NXGL's ROE of -0.63%. Regarding short-term risk, XRAY is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check NXGL's competition here
XRAY vs MHUA Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, MHUA has a market cap of 12.2M. Regarding current trading prices, XRAY is priced at $16.03, while MHUA trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas MHUA's P/E ratio is 0.96. In terms of profitability, XRAY's ROE is -0.38%, compared to MHUA's ROE of +0.09%. Regarding short-term risk, XRAY is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check MHUA's competition here
XRAY vs EKSO Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, EKSO has a market cap of 11.6M. Regarding current trading prices, XRAY is priced at $16.03, while EKSO trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas EKSO's P/E ratio is -0.67. In terms of profitability, XRAY's ROE is -0.38%, compared to EKSO's ROE of -0.82%. Regarding short-term risk, XRAY is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check EKSO's competition here
XRAY vs LUCY Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, LUCY has a market cap of 9.7M. Regarding current trading prices, XRAY is priced at $16.03, while LUCY trades at $2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas LUCY's P/E ratio is 0.05. In terms of profitability, XRAY's ROE is -0.38%, compared to LUCY's ROE of -0.95%. Regarding short-term risk, XRAY is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check LUCY's competition here
XRAY vs POAI Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, POAI has a market cap of 8.1M. Regarding current trading prices, XRAY is priced at $16.03, while POAI trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas POAI's P/E ratio is -0.55. In terms of profitability, XRAY's ROE is -0.38%, compared to POAI's ROE of -5.91%. Regarding short-term risk, XRAY is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check POAI's competition here
XRAY vs STSS Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, STSS has a market cap of 6.3M. Regarding current trading prices, XRAY is priced at $16.03, while STSS trades at $6.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas STSS's P/E ratio is N/A. In terms of profitability, XRAY's ROE is -0.38%, compared to STSS's ROE of -0.99%. Regarding short-term risk, XRAY is more volatile compared to STSS. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check STSS's competition here
XRAY vs NSTG Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, XRAY is priced at $16.03, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas NSTG's P/E ratio is -0.03. In terms of profitability, XRAY's ROE is -0.38%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, XRAY is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check NSTG's competition here
XRAY vs GCTK Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, GCTK has a market cap of 4.2M. Regarding current trading prices, XRAY is priced at $16.03, while GCTK trades at $7.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas GCTK's P/E ratio is N/A. In terms of profitability, XRAY's ROE is -0.38%, compared to GCTK's ROE of +3.93%. Regarding short-term risk, XRAY is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check GCTK's competition here
XRAY vs GMVD Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, XRAY is priced at $16.03, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas GMVD's P/E ratio is -0.01. In terms of profitability, XRAY's ROE is -0.38%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, XRAY is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check GMVD's competition here
XRAY vs GMVDW Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, XRAY is priced at $16.03, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas GMVDW's P/E ratio is N/A. In terms of profitability, XRAY's ROE is -0.38%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, XRAY is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check GMVDW's competition here
XRAY vs AVGR Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, XRAY is priced at $16.03, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas AVGR's P/E ratio is -0.05. In terms of profitability, XRAY's ROE is -0.38%, compared to AVGR's ROE of -54.25%. Regarding short-term risk, XRAY is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check AVGR's competition here
XRAY vs LUCYW Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, LUCYW has a market cap of 150.2K. Regarding current trading prices, XRAY is priced at $16.03, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas LUCYW's P/E ratio is N/A. In terms of profitability, XRAY's ROE is -0.38%, compared to LUCYW's ROE of -0.95%. Regarding short-term risk, XRAY is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for XRAY.Check LUCYW's competition here
XRAY vs HRC Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, HRC has a market cap of 0. Regarding current trading prices, XRAY is priced at $16.03, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas HRC's P/E ratio is 41.92. In terms of profitability, XRAY's ROE is -0.38%, compared to HRC's ROE of +0.14%. Regarding short-term risk, XRAY is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check HRC's competition here
XRAY vs APR Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, APR has a market cap of 0. Regarding current trading prices, XRAY is priced at $16.03, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas APR's P/E ratio is 22.59. In terms of profitability, XRAY's ROE is -0.38%, compared to APR's ROE of +9.81%. Regarding short-term risk, XRAY is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check APR's competition here
XRAY vs ATRS Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, XRAY is priced at $16.03, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas ATRS's P/E ratio is 14.95. In terms of profitability, XRAY's ROE is -0.38%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, XRAY is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check ATRS's competition here
XRAY vs IIN Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, IIN has a market cap of 0. Regarding current trading prices, XRAY is priced at $16.03, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas IIN's P/E ratio is 226.45. In terms of profitability, XRAY's ROE is -0.38%, compared to IIN's ROE of -0.00%. Regarding short-term risk, XRAY is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check IIN's competition here
XRAY vs LMNX Comparison July 2025
XRAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRAY stands at 3.2B. In comparison, LMNX has a market cap of 0. Regarding current trading prices, XRAY is priced at $16.03, while LMNX trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRAY currently has a P/E ratio of -3.59, whereas LMNX's P/E ratio is N/A. In terms of profitability, XRAY's ROE is -0.38%, compared to LMNX's ROE of +0.03%. Regarding short-term risk, XRAY is more volatile compared to LMNX. This indicates potentially higher risk in terms of short-term price fluctuations for XRAY.Check LMNX's competition here